Medication evidence profile
Moclobemide
Clinical overview
Moclobemide has public medication-list entries in Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement. These are 3 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | Not listed |
| BAAS | Not listed |
| Swe-ABS | 0 |
| GABS | 0 |
| KABS | 0 |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
Other names used in the sources
Moclobemid
How to interpret the evidence
3 of 7 public source versions contain an explicit medication-list entry for moclobemide.
The available rows for moclobemide display the same numeric value. Agreement of the displayed numbers does not establish identical methods, clinical meaning or patient-level risk.
Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement explicitly record zero. Those recorded zeros remain different from a missing entry.
Source labels and provenance · 3 observations
- Swedish Anticholinergic Burden Scale 2023
Source label: Moclobemide. Published value: 0.
Source version: SWE-ABS-2023
Source location: 12877_2023_4225_MOESM1_ESM.docx ST3 row 160
Observation: SWE_ABS_2023_R0285; rating state: published_zero. - German Anticholinergic Burden Score 2018
Source label: Moclobemid. Published value: 0.
Source version: GABS-2018
Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 223
Observation: GABS_2018_R0373; rating state: published_zero. - KABS 2019 scale - 2020 open validation supplement
Source label: Moclobemide. Published value: 0.
Source version: KABS-2020-validation-supplement
Source location: Additional file 1; category Antidepressants; table row 10
Observation: KABS2020_SUPP_0037; rating state: published_zero.
What this page does not establish
- No medication-list entry is available here from JARS 2025, Yamada-ABS 2023, BAAS 2019, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
- Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Moclobemide
Ask about this medication